SOPHiA GENETICS SA (NASDAQ:SOPH) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET

Company Participants

Jennifer Pottage - Head of IR

Jurgi Camblong - Co-Founder, CEO and Director

Ross Muken - Senior VP and CFO

Conference Call Participants

Dan Brennan - Cowen

Tejas Savant - Morgan Stanley

Julia Chen - JPMorgan

Operator

Thank you for standing by, and welcome to the SOPHiA GENETICS First Quarter Fiscal 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions]

I would now like to hand the call over to Jennifer Pottage, Head of Investor Relations.

Jennifer Pottage

Good morning, and thank you for joining us on SOPHiA GENETICS Q1 Fiscal 2022 Earnings Call. My name is Jennifer Pottage, and I'm the Head of Investor Relations at SOPHiA. Joining me today are Dr. Jurgi Camblong, our Co-Founder and Chief Executive Officer; and Ross Muken, our Chief Financial Officer.

Before we get started, I would like to remind you that management will make statements during the call that are forward-looking within the scope of U.S. federal securities laws. These statements are based on management's current views and assumptions, which are subject to material risks and uncertainties that could cause actual results or events to differ materially from those projected. Additional information regarding these risks and uncertainties are included in the section entitled Cautionary Statement regarding forward-looking statements and Exhibit 99.2 of the report on Form 6-K filed with the SEC.

Except as required by law, SOPHiA GENETICS disclaims any intention or obligation to update or revise any forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of its broadcast, May 10, 2022. Please note, both the replay of this call as well as the earnings release and associated slides will be available on our website in the Investors section.

And now I'll turn the call over to Jurgi.

Jurgi Camblong

Thank you, Jenn. Good morning, everyone. I'm happy to be here with you today to share the excellent performance SOPHiA delivered during Q1. As announced last month, we reached an incredible milestone. We now have over 1 million genomic profiles analyzed on the SOPHiA DDM platform, further strengthening our position as a leading cloud-native, knowledge sharing platform, connecting thousands of health care professionals worldwide. As one of the founders of SOPHiA, it brings me immense joy to reflect on the progress we have made. We have come a long way since 2011 from just a handful of people in a 10 square meter room with a vision to democratize data-driven medicine.